Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients

H. Lhotska, K. Janeckova, H. Cechova, J. Macoun, T. Aghova, L. Lizcova, K. Svobodova, L. Hodanova, D. Konecna, J. Soukup, F. Kramar, D. Netuka, Z. Zemanova

. 2025 ; 17 (1) : 16. [pub] 20250129

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, validační studie, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010164

Grantová podpora
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
NU21-04-00100 Agentura Pro Zdravotnický Výzkum České Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO 0064165 Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: Glioblastoma is the commonest malignant brain tumor and has a very poor prognosis. Reduced expression of the MGMT gene (10q26.3), influenced primarily by the methylation of two differentially methylated regions (DMR1 and DMR2), is associated with a good response to temozolomide treatment. However, suitable methods for detecting the methylation of the MGMT gene promoter and setting appropriate cutoff values are debated. RESULTS: A cohort of 108 patients with histologically and genetically defined glioblastoma was retrospectively examined with methylation-specific Sanger sequencing (sSeq) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) methods. The DMR2 region was methylated in 29% of samples, whereas DMR1 was methylated in 12% of samples. Methylation detected with the MS-MLPA method using probes MGMT_215, MGMT_190, and MGMT_124 from the ME012-A1 kit (located in DMR1 and DMR2) correlated with the methylation of the corresponding CpG dinucleotides detected with sSeq (p = 0.005 for probe MGMT_215; p < 0.001 for probe MGMT_190; p = 0.016 for probe MGMT_124). The threshold for methylation detection with the MS-MLPA method was calculated with a ROC curve analysis and principal components analysis of the data obtained with the MS-MLPA and sSeq methods, yielding a weighted value of 0.362. Thus, methylation of the MGMT gene promoter was confirmed in 36% of samples. These patients had statistically significantly better overall survival (p = 0.003). CONCLUSIONS: Our results show that the threshold for methylation detection with the MS-MLPA method determined here is useful from a diagnostic perspective because it allows the stratification of patients who will benefit from specific treatment protocols, including temozolomide. Detailed analysis of the MGMT gene promoter enables the more-precise and personalized treatment of patients with glioblastoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010164
003      
CZ-PrNML
005      
20250429135351.0
007      
ta
008      
250415s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13148-025-01822-2 $2 doi
035    __
$a (PubMed)39881389
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Lhotska, Halka $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic
245    10
$a Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients / $c H. Lhotska, K. Janeckova, H. Cechova, J. Macoun, T. Aghova, L. Lizcova, K. Svobodova, L. Hodanova, D. Konecna, J. Soukup, F. Kramar, D. Netuka, Z. Zemanova
520    9_
$a BACKGROUND: Glioblastoma is the commonest malignant brain tumor and has a very poor prognosis. Reduced expression of the MGMT gene (10q26.3), influenced primarily by the methylation of two differentially methylated regions (DMR1 and DMR2), is associated with a good response to temozolomide treatment. However, suitable methods for detecting the methylation of the MGMT gene promoter and setting appropriate cutoff values are debated. RESULTS: A cohort of 108 patients with histologically and genetically defined glioblastoma was retrospectively examined with methylation-specific Sanger sequencing (sSeq) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) methods. The DMR2 region was methylated in 29% of samples, whereas DMR1 was methylated in 12% of samples. Methylation detected with the MS-MLPA method using probes MGMT_215, MGMT_190, and MGMT_124 from the ME012-A1 kit (located in DMR1 and DMR2) correlated with the methylation of the corresponding CpG dinucleotides detected with sSeq (p = 0.005 for probe MGMT_215; p < 0.001 for probe MGMT_190; p = 0.016 for probe MGMT_124). The threshold for methylation detection with the MS-MLPA method was calculated with a ROC curve analysis and principal components analysis of the data obtained with the MS-MLPA and sSeq methods, yielding a weighted value of 0.362. Thus, methylation of the MGMT gene promoter was confirmed in 36% of samples. These patients had statistically significantly better overall survival (p = 0.003). CONCLUSIONS: Our results show that the threshold for methylation detection with the MS-MLPA method determined here is useful from a diagnostic perspective because it allows the stratification of patients who will benefit from specific treatment protocols, including temozolomide. Detailed analysis of the MGMT gene promoter enables the more-precise and personalized treatment of patients with glioblastoma.
650    _2
$a lidé $7 D006801
650    12
$a glioblastom $x genetika $x farmakoterapie $7 D005909
650    12
$a metylace DNA $x genetika $7 D019175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádorové supresorové proteiny $x genetika $7 D025521
650    12
$a enzymy opravy DNA $x genetika $7 D045643
650    12
$a DNA modifikační methylasy $x genetika $7 D015254
650    _2
$a senioři $7 D000368
650    12
$a promotorové oblasti (genetika) $x genetika $7 D011401
650    12
$a nádory mozku $x genetika $7 D001932
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    _2
$a temozolomid $x terapeutické užití $7 D000077204
650    _2
$a sekvenční analýza DNA $x metody $7 D017422
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a CpG ostrůvky $x genetika $7 D018899
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Janeckova, Karolina $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic
700    1_
$a Cechova, Hana $u Department of HLA, Institute of Hematology and Blood Transfusion, U Nemocnice 2094/1, 128 00, Prague, Czech Republic
700    1_
$a Macoun, Jaromir $u The Clinical Trials and Research Department, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic
700    1_
$a Aghova, Tatiana $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic
700    1_
$a Lizcova, Libuse $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic
700    1_
$a Svobodova, Karla $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic
700    1_
$a Hodanova, Lucie $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic
700    1_
$a Konecna, Dora $u Department of Neurosurgery and Neurooncology, 1st Faculty of Medicine of Charles University and Military University Hospital Prague, U Vojenske Nemocnice 1200, 169 02, Prague, Czech Republic
700    1_
$a Soukup, Jiri $u Department of Pathology, 1st Faculty of Medicine of Charles University and Military University Hospital Prague, U Vojenske Nemocnice 1200, 169 02, Prague, Czech Republic $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Kramar, Filip $u Department of Neurosurgery and Neurooncology, 1st Faculty of Medicine of Charles University and Military University Hospital Prague, U Vojenske Nemocnice 1200, 169 02, Prague, Czech Republic
700    1_
$a Netuka, David $u Department of Neurosurgery and Neurooncology, 1st Faculty of Medicine of Charles University and Military University Hospital Prague, U Vojenske Nemocnice 1200, 169 02, Prague, Czech Republic
700    1_
$a Zemanova, Zuzana $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, U Nemocnice 499/2, 128 00, Prague, Czech Republic. zuzana.zemanova@vfn.cz
773    0_
$w MED00186202 $t Clinical epigenetics $x 1868-7083 $g Roč. 17, č. 1 (2025), s. 16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39881389 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135347 $b ABA008
999    __
$a ok $b bmc $g 2311507 $s 1247245
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 17 $c 1 $d 16 $e 20250129 $i 1868-7083 $m Clinical epigenetics $n Clin Epigenetics $x MED00186202
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU21-04-00100 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MH CZ - DRO 0064165 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace